Management overview
Prevention of progression
Presentation of renal failure
Complications of renal failure
Complications
Indications for dialysis
HAVE PEE or AE IOU
Hyperkalemia (refractory)
Acidosis (refractory)
Volume overload (refractory)
Elevated urea (>35-50 mM)
Pericarditis
Encephalopathy
Edema (pulmonary)
Number of people on RRT, number at risk of CKD, number of people with CKD
Risk factors
Screening for CKD in ATSI
Systemic manifestations
Renal replacement therapy in acute setting indications
Hemofiltration or hemodialysis
Renal replacement therapy chronic: reasons for one over the other
Risks: hemodynamic instability, bleeding, sepsis, hypersensitivity, air embolus, arrythmias
Complications and associated management: HTN, bone, albuminuria, glycemic control, anemia
Phosphate diet restriction (get dietician help)-> cheese, milk, eggs, use phosphate binders (Calcium carbonate)
Consider calcitriol in later stages.
If phosphate controlled, calcium leves usually improve.
Hypoglycemics, diet, insulin, incretins, gliptins
Need neprhologist.
Iron supplement
Rule out other causes->Vit B12, folate, TSH
Mangement of complications: uremia, restless leg, hyperkalemia, sleep apnea, depression, acidosis
Dialysis when urea ++
Low protein diet, fluid control
Antiemetics have limited value
Iron supplementation, baths and massages, compresses, levodopa, benzodiazepines
Low K diet, correct acidosis, K wasting diuretics, resonium A powder, cease ACEi/ARB/Spirinolacton if >6.
?Sodium bicarbonate
Weight loss
Avoid CNS depressants
CPAP
Psychosocial intervention
Antidepressants at low dose
Medications in CKD: drugs needing reduction, affects on kidney
Anticoagulants–>dabigatran
Antivirals
Benzodiazepines, gabapentin, lithium
Colchicine
Digoxin
Exenatide, insuin, metformin
Sotolol, spirinolactone
Sulfonylureas
Opioid analgesics
Digoxin, fenofibrate
Saxagliptin (DPP-4 inibitors)
Contrast
NSAIDs, COX 2 i, ACE, diuretics->tripple whammy
Aminoglycosides
Lithium
Calcinuerin
Definition
Screening test for CKD
DIfferential for +ACR
UTI- dipstick, Acute febrile illness - T
+Dietary protein- Hx, ++exercise last
24 hours- Hx
Mensturation/vaginal discharge- Hx
NSAIDS- Hx, Congestive, cardiac failure
Is eGFR clinically reliable
If abnormal eGFR
Management action plans: yellow, orange, red
Annual review:
a) exclude treatable, adress CVD, avoid nephrotoxic drugs
b) BP, lifestyle
c) Urine ACR, UEC, BUN, eGFR, HbA1C, statins
2. Orange 30-60 w/ micro >30-44
3-6 monthly
a) Same as yellow + detect complications, adjust medication doses, refer when indicated
b) +FBC, CMP, PTH when <45 + Urine ACR, UEC, BUN, eGFR, HbA1C, statins
3. Red action plan
MacroA, eGFR <30
1-3 monthly review
a) Same goals, + referall + prepare for dialysis + AHD
b) Same investigations + edema, +advanced care planning
Stages
Stage 1: kidney damage with normal or increased GFR, ≥90 mL/minute/1.73m^2
Stage 2: kidney damage with mild decrease in GFR, 60 to 89 mL/minute/1.73m^2
Stage 3a: kidney damage with moderate decrease in GFR, 45 to 59 mL/minute/1.73m^2
Stage 3b: kidney damage with moderate decrease in GFR, 30 to 44 mL/minute/1.73m^2
Stage 4: kidney damage with severe decrease in GFR, 15 to 29 mL/minute/1.73m^2
Stage 5: kidney failure (end-stage kidney disease), with GFR <15 mL/minute/1.73m^2
Define acute renal failure
Acute kidney injury is defined by a rise in the serum creatinine of ≥23 micromol/L (≥0.3 mg/dL) from baseline, a 50% increase in serum creatinine from baseline, or a reduction in urine output of <0.5 mL/kg/hour for more than 6 hours that occurs over a period of days to weeks.
Counselling use of ACEi
stop potassium supplements and potassium-sparing diuretics
in heart failure, consider reducing dose or withholding other diuretics for 24 hours before starting an ACE inhibitor
review use of NSAIDs (including selective COX‑2 inhibitors)
start with a low dose
check renal function and electrolytes before starting an ACE inhibitor and review after 1–2 weeks